Generated by AI
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for serious, rare skin diseases and vascular malformations with no FDA-approved treatment options. The company centers its work on dermatology-focused rare disease programs, using its proprietary QTORIN platform to create topical therapies designed for localized delivery in difficult-to-treat conditions. Its current pipeline includes product candidates being studied for microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas, reflecting a focus on genetically driven and orphan skin disorders. Palvella Therapeutics serves the rare disease and specialty dermatology markets, where targeted medicines can address conditions that are often chronic, burdensome, and underserved by existing therapies. Palvella Therapeutics, Inc. is headquartered in Wayne, Pennsylvania.
Website353 W. Lancaster Avenue
Wayne, PA, 19087
United States
The latest articles about PVLA.
Third product candidate from Palvella’s QTORIN™ platform to be announced Live audiovisual webcast to take place tomorrow, Thursday, November 19, 2026, at 8:30 a.m. ET WAYNE, Pa., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Nasdaq: PVLA) (“Palvella” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration
Summary of Mar 31's posts. Generated by AI.
No summary yet.
Summary of Feb 25's posts. Generated by AI.
Summary of Mar 31's posts. Generated by AI.
Investors talking about PVLA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.